Latest news for Iris Acquisition (NASDAQ:IRAA) Stock

Iris Acquisition Corp is a blank check company.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

APLS

HTBI

IRAA

JELD

LNZA

MHUA

MVBF

PROC

SGML

TVTX

U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.

Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday

Iris Acquisition Corp - Class A Common Stock

Iris Acquisition Corp

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $32 to $26.

Price Target

Analyst Ratings

IART

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $26

Backed By Alberta Indigenous Opportunities Corporation, Implied Enterprise Value Of $1.65B

TC Energy Announces $1B Equity Interest Purchase Agreement With Indigenous Investment Partnership For 5.34% Stake In NGTL And Foothills Pipeline Assets

<ul>
<li>Ongoing open-label extension trials of simufilam in Alzheimer's disease to be extended by up to an additional 36 months.</li>
<li>The extension provides participants the opportunity to continue on treatment, if they desire, pending results of the ongoing pivotal Phase 3 trials.</li>
<li>Company plans to add cognition and plasma biomarker monitoring to the open-label extension trials to gather additional long-term data on simufilam treatment.</li>
</ul>
AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) today announced that the Company will extend by up to an additional 36 months each of the open-label extension trials in its ongoing Phase 2 and Phase 3 clinical programs. These amendments to the protocols will allow patients who have previously participated in a randomized trial of simufilam in Alzheimer's disease, if they desire, to continue open-label treatment with simufilam. This expansion of the open-label extension trials offers a bridge for any gap between patients ending treatment in a clinical trial and the Company reporting to regulatory authorities the results of the ongoing, randomized, placebo-controlled Phase 3 trials. The open-label extension can continue for up to 36 months or until a new drug application for simufilam has been reviewed by FDA.

Biotech

General

SAVA

Cassava Sciences Announces Expansion Of Open-Label Extension Trials By Up To An Additional 36 Months To Provide Participants The Opportunity To Continue On Treatment, If They Desire, Pending Results Of The Ongoing Phase 3 Trials

BGC Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGC#NASDAQ">BGC</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is a 15 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $550.76 million which beat the analyst consensus estimate of $545.00 million by 1.06 percent. This is a 11.70 percent increase over sales of $493.08 million the same period last year.

Earnings

Earnings Beats

BGC Partners Q2 Adj $0.23, Inline, Sales $550.76M Beat $545.00M Estimate

WIIM

FBMS

First Bancshares are trading higher after the company announced it will be acquired by Renasant Corporation in an all-stock transaction valued at $1.2 billion.

Benchmark analyst Mark Zgutowicz reiterates DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Buy and maintains $150 price target.

Reiteration

DASH

Benchmark Reiterates Buy on DoorDash, Maintains $150 Price Target

SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the cerebral spinal fluid (CSF) of Alzheimer's patients; an important finding since increased α-syn has been correlated with worse cognitive performance and is not a target for any currently approved Alzheimer's treatments &nbsp;
SNK01 treatment appears to stabilize or improve cognitive function and reduce α-synuclein levels in CSF in addition to improving previously reported amyloid, tau, and neuroinflammatory markers (GFAP, NfL, YKL-40) in the majority of patients
SANTA ANA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the presentation of a poster entitled, "Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF α-synuclein and in cognitive function." SNK01 is a first-in-kind, autologous non-genetically modified NK cell product with significantly increased cytotoxicity and over 90% activating receptor expression that can be consistently produced from any donor. Clinical trial data on the effect of SNK01 α-synuclein and cognitive assessments in patients with Alzheimer's Disease ("AD") was presented at the 2024 Alzheimer's Association International Conference ("AAIC") held in Philadelphia, PA on July 30, 2024.

NKGN

NKGen Biotech Presents New SNK01 Biomarker Data At The 2024 AAIC Held On July 30, 2024

Easy Installation And Significant Performance Enhancements

COMM

CommScope Launches STARLINE 1.8 GHz ESD Amplifiers For DOCSIS 3.1 Networks; Provides Upgrade Path To DOCSIS 4.0

NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.64 by 6.25 percent. The company reported quarterly sales of $64.200 million which missed the analyst consensus estimate of $64.750 million by 0.85 percent. This is a 7.76 percent decrease over sales of $69.600 million the same period last year.

Earnings Misses

NXRT

NexPoint Residential Q2 2024 FFO $0.68 Beats $0.64 Estimate, Sales $64.200M Miss $64.750M Estimate

Truist Securities analyst Michael Lewis maintains Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) with a Buy and raises the price target from $29 to $33.

Truist Securities Maintains Buy on Highwoods Props, Raises Price Target to $33

In the picturesque town of Seeley Lake, Montana, surrounded by beautiful forests, Pyramid Mountain Lumber has been the heartbeat of the community for 75 years. But now, despite abundant wood, the mill is closing its doors for the most surprising reason: the town lacks a centralized sewer system.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
</ul>
Pyramid Mountain Lumber, the town's biggest employer, has been a family-owned business since 1948. Todd Johnson, whose grandfather started the mill, has worked there his entire life. &#8220;I&#8217;ve never drawn a paycheck from any other business in my whole life. I started here in sixth grade,&#8221; Johnson shared. &#8220;This is all I&#8217;ve ever known.&#8221;
The closure is not due to political battles or environmental issues. Instead, it's because the town doesn&#8217;t have a centralized sewer system, which prevents new affordable housing from being built. This makes it difficult to attract and retain workers.&nbsp;
Johnson explains, &#8220;There hasn&#8217;t been an apartment, duplex, or fourplex built in this town in over 30 years, so … when you&#8217;re talking about entry-level housing for more blue-collar workers, there&#8217;s just none available.&#8221;
Trending: Finally allowing commercial real estate investing to be more accessible —<a href="https://www.benzinga.com/money/equitymultiple-ascent-fund"> This fund aims to triple your money in 10 years is with a surprisingly low minimum.</a>
Missoula County officials explain that developers can&#8217;t build cost-effective housing for the mill's blue-collar workers without a sewer system. High-end septic systems are too expensive for the kind of housing needed in Seeley Lake. The town has debated installing a sewer system for years, but residents have consistently voted against it due to concerns about costs and changing the town&#8217;s character.
The impact of this decision is now hitting home. Pyramid Mountain Lumber, which cuts various sizes of lumber and has grown significantly over the decades, cannot find enough workers to keep running. &#8220;To make the announcement to the crew was probably the toughest thing,&#8221; Johnson told ABC News. &#8220;I&#8217;ve got friends, family, generations of good friends that work here. I had to tell them we&#8217;re going to shut the doors.&#8221;
The shortage of workers isn't just affecting the mill. Kyle Marx, the general manager of Rovero's Hardware, mentioned they&#8217;re &#8220;running on a skeleton crew&#8221; during their busiest season. &#8220;No affordable housing here,&#8221; Marx said. &#8220;Rentals have diminished since COVID hit, and everybody came up here, bought every rental that was available, and turned them into vacation rentals or moved up here themselves.&#8221;
See Also: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
Dee Baker, who owns the Grizzly Claw Trading Company, said this has been a problem for years. "There could be low-income housing built, but the people in the town cannot come to an agreement with Missoula County," she said.
Dave Strohmaier, chair of the Missoula Board of County Commissioners, explained the irony of the situation. &#8220;The lack of infrastructure is a big reason why Pyramid Mountain Lumber cannot find housing for their employees, and hence, change is upon us,&#8221; he said.
With the mill's payroll contributing over $6 million a year to the local economy, its closure will change the fabric of Seeley Lake. &#8220;You take that out of this economy, it&#8217;ll change the fabric of the town. There&#8217;s no doubt,&#8221; Johnson noted.
Although surrounded by abundant natural resources, Seeley Lake faces a future where its long-standing timber industry might disappear, all because there isn't a place for workers to live.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that lets you seize the private credit boom.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>

Real Estate

Although There's An Abundance Of Wood, This 75-Year-Old Mill In Montana Is Closing For The Most Surprising Reason

aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim's research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme (GBM).

ATYR

aTyr Pharma Announces Research Study with Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme

Truist Securities analyst Anthony Hau maintains Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) with a Hold and raises the price target from $65 to $70.

Truist Securities Maintains Hold on Equity Lifestyle Props, Raises Price Target to $70

HEES

H&E Equipment Services shares are trading lower after the company reported worse-than-expected Q2 financial results.

<ul>
<li>Launching into this growth market1 as part of the company's geographic expansion strategy</li>
<li>Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evolus.com%2F&amp;esheet=54099911&amp;newsitemid=20240730657453&amp;lan=en-US&amp;anchor=Evolus%2C+Inc.&amp;index=1&amp;md5=1f4593444d661564b0233037f1f5dd5a">Evolus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva&#xAE; (prabotulinumtoxinA).
Nuceiva&#xAE; is approved by the Therapeutic Goods Administration (TGA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2.

Global

EOLS

Evolus Expands Global Footprint With Introduction Of Nuceiva In Australia

Truist Securities analyst Anthony Hau maintains Alpine Income Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Hold and raises the price target from $16 to $18.

PINE

Truist Securities Maintains Hold on Alpine Income Prop Trust, Raises Price Target to $18

Charles River Laboratories Partners With FOXG1 Research Foundation To Advance AAV9 Gene Therapy Clinical Trials; Collaboration Leverages Plasmid And Viral Vector CDMO Expertise To Drive Drug Development For FOXG1 Syndrome And Related Neurological Disorders

Barclays analyst Saket Kalia maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Overweight and raises the price target from $55 to $60.

VRNS

Barclays Maintains Overweight on Varonis Systems, Raises Price Target to $60

NUBURU, Inc. ("NUBURU" or the "Company") (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BURU#OTC">BURU</a>), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced that, on July 29, 2024, it received a notification from NYSE American LLC ("NYSE American") informing Nuburu that it has resolved the continued listing deficiency with respect to low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide. As a result, the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension on Nuburu's common stock on NYSE American. The common stock will commence trading on NYSE American on Friday, August 2, 2024 under the symbol "BURU" and CUSIP "67021W301".

BURU

NUBURU Announces Removal Of Trading Suspension; Will Commence Trading On NYSE American On Friday, August 2, 2024 Under The Symbol "BURU"

JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) stock gained after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b40031524/jetblue-announces-second-quarter-2024-results" rel="noreferrer noopener">better-than-expected second-quarter 2024 results</a>.
The air carrier reported a second-quarter adjusted EPS of $0.08, above the consensus loss of $0.13, and <a href="https://www.benzinga.com/earnings">compared to EPS of $0.45 reported a year ago.</a>
JetBlue reported operating revenue of $2.428 billion, down 6.9% year over year, beating the consensus of $2.397 billion. Second quarter system capacity decreased by 2.7% year over year.
&#8220;In the second quarter, we continued to implement our JetForward strategy with the announcement of more significant network changes&#8230; As we progress through the second half of the year, we&#8217;ll be announcing additional initiatives designed to further enhance our customer value proposition, close the gap in our product offering to our peers, and drive significant financial benefit,&#8221; commented Marty St. George, JetBlue&#8217;sJetBlue&#8217;s president.
The operating margin for the quarter declined 670 bps to 2.3%, and the adjusted operating margin stood at 2.4%, down YoY from 9.9%.
Operating expenses for the quarter declined slightly by 0.1% to $2.37 billion, while the operating expenses per available seat mile (CASM) rose 2.6% YoY.
Adjusted operating expenses rose 0.9% to $1.73 billion. Operating expenses per available seat mile, excluding fuel and other non-airline operating expenses, increased by 3.7% YoY.
JBLU&#8217;s Average fuel price in the second quarter was $2.87 per gallon, up from $2.73 a year ago.
The airline ended the quarter with ~$1.6 billion in liquidity, excluding an undrawn $600 million revolving credit facility.
JBLU delivered improved operational performance year-over-year with a completion factor of 98.8%, up from 97.8% YoY.
&#8220;While many of these underlying initiatives will take time to ramp to their full potential, with the strong foundation of JetForward, we are poised to generate $800 &#8211; $900 million of incremental EBIT from 2025 through 2027 and expect the benefit to be realized evenly over those three years,&#8221; said Ursula Hurley, JetBlue&#8217;s chief financial officer.
&#8220;We are setting ourselves on a path to restore our balance sheet health, and in support of securing our financial future, we are announcing an incremental aircraft deferral of approximately $3 billion of planned capital expenditures. Our focus will be on driving value from our existing asset base and, ultimately, generating positive free cash flow,&#8221; Hurley added.
Q3 Guidance: JetBlue anticipates a year-over-year revenue drop of 5.5% to 1.5%; <a href="https://www.benzinga.com/calendars/guidance">Available Seat Miles (ASMs) are expected to decrease by 6% to 3% YoY.</a>
CASM ex-fuel is projected to rise 6% to 8%, and the expected fuel price per gallon is between $2.82 and $2.97.
2024 Guidance: JetBlue anticipates a year-over-year revenue drop of 6% to 4% (prior view: Down low single digits); Available Seat Miles (ASMs) are expected to decrease by 5% to 2.5% YoY (prior view: Down low single digits).
2024 CASM ex-fuel is expected to increase 6.5% to 8.5%; the projected fuel price per gallon is between $2.80 and $3.00.
Price Action: JBLU shares are trading higher by 4.22% to $6.18 premarket at the last check Tuesday.
Photo via Wikimedia Commons

Guidance

JBLU

JetBlue Q2 Earnings: Revenue And EPS Beat, Unveils JetForward Strategy, Targets $800M-$900M Incremental EBIT By 2027

Press Releases

Legion Partners Issues Letter to The Chefs' Warehouse, Inc. Shareholders Calling for Urgently Needed Board Change

AMPS

CHEF

LFCR

USFD

Iris Acquisition

U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today&rsquo;s session.

<ul>
	<li>LanzaTech Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) jumped 27.7% to $5.30.</li>
	<li>Helix Energy Solutions Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) climbed 17.7% to $8.98 after the company posted a profit for the fourth quarter.</li>
	<li>Procaps Group S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) gained 14% to $4.72.</li>
	<li>Travere Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) climbed 13.6% to $20.24. The FDA granted accelerated approval to Travere Therapeutics&rsquo; Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.</li>
	<li>Sigma Lithium Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) jumped 13.1% to $33.34 following reports that Tesla is considering a bid for the battery metals mining company.</li>
	<li>Dingdong (Cayman) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDL#NYSE">DDL</a>) rose 12.2% to $5.07.</li>
	<li>The Manitowoc Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTW#NYSE">MTW</a>) surged 11.8% to $16.06 after reporting Q4 results.</li>
	<li>Apellis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) shares gained 11.4% to $61.96 after the company said that the FDA approved SYFOVRE as first and only treatment for geographic atrophy.</li>
	<li>Meihua International Medical Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) climbed 10.2% to $28.67.</li>
	<li>Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) rose 9.8% to $28.27 after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $41 to $53.</li>
	<li>Iris Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRAA#NASDAQ">IRAA</a>) gained 9.5% to $11.02.</li>
	<li>HomeTrust Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBI#NASDAQ">HTBI</a>) surged 7.9% to $30.30. Janney Montgomery Scott upgraded HomeTrust Bancshares from Neutral to Buy.</li>
	<li>Atlantica Sustainable Infrastructure plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AY#NASDAQ">AY</a>) jumped 7.7% to $27.91.</li>
	<li>JELD-WEN Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) gained 7% to $13.77 following better-than-expected quarterly earnings.</li>
	<li>MVB Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVBF#NASDAQ">MVBF</a>) gained 6.8% to $25.83. MVB Financial, on Friday, posted Q4 EPS of $0.50.</li>
</ul>

Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/23/02/30988689/ethereum-falls-but-remains-above-1-600-blur-filecoin-among-top-losers"> Ethereum Falls But Remains Above $1,600; Blur, Filecoin Among Top Losers</a>

Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma

The transaction values the combined companies at a pro forma enterprise value of&nbsp;$334 million

The&nbsp;immune-modulating cancertreatments being developed by Liminatus are a&nbsp;GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor. The GCC vaccine and CAR-T patent portfolio originated from Thomas Jefferson University (TJU). The CD47 checkpoint inhibitor originates from a South Korean biotech company InnoBation Bio Co. Ltd.

The transaction is expected to be completed in the first half of 2023

Liminatus Pharma LLC (&quot;Liminatus&quot;), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp (&quot;Iris&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRAA#NASDAQ">IRAA</a>), a publicly traded special purpose acquisition company (&quot;SPAC&quot;) formed for the purpose of acquiring or merging with one or more businesses, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed &quot;Liminatus Pharma, Inc.&quot;. The combined company&#39;s common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a&nbsp;$15 million&nbsp;common stock PIPE financing and a&nbsp;$25 million&nbsp;convertible note financing to further support Liminatus&#39; business growth strategy.

As part of the agreement the new entity is expected to develop three much-needed cancer treatments which have originated from the Thomas Jefferson University (TJU) in the US anda South Korean biotech firm, Innobation Bio Ltd. (&quot;Innobation&quot;). The lead product candidate, the GCC Vaccine is currently in Phase II clinical trials and is designed to elicit immune responses against colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C (&quot;GCC&quot;). Further to the work in this area, Liminatus expects to use the increased capital from this agreement to progress its GCC CAR-T therapy to a first in human clinical trial, and complete IND enabling studies for its next generation CD47 immune checkpoint inhibitor.

About the Transaction

The business combination implies a pro forma enterprise value of the combined company of approximately&nbsp;$334 million. The combined company is expected to receive gross cash proceeds of up to&nbsp;$316 million, comprising the&nbsp;$276 million&nbsp;held in Iris&#39; trust account (assuming no redemptions by public shareholders of Iris) and a concurrent, committed&nbsp;$15 million&nbsp;equity PIPE financing of common stock issued at&nbsp;$10.00&nbsp;per share and&nbsp;$25 million&nbsp;convertible note financing with an initial conversion rate of&nbsp;$11.50&nbsp;per share of common stock, subject to future adjustments based upon the price of Iris&#39; publicly traded common stock. The combined company will bear deferred underwriting commissions and transaction expenses out of the gross proceeds.

The transaction, which has been approved by Liminatus&#39;s and Iris&#39; boards of directors, is expected to close in the first half of 2023, subject to review by the Securities and Exchange Commission (&quot;SEC&quot;) and effectiveness of the registration statement on Form S-4 to be filed with the SEC, approval by Iris&#39; shareholders, and satisfaction of the closing conditions set forth in the business combination agreement, including any applicable regulatory approvals.

&quot;The agreement with Iris and the treatments we are now set to develop which have originated from leading global cancer scientists at the Thomas Jefferson University in the US and from Innobation in South Korea, will be a game changer for this area of the healthcare market. There is a significant unmet need for improved treatment for the cancer indications we are targeting, and with the increased capital, we are hopeful that the timelines for getting these potentially life-saving medicines to market have been accelerated&quot;,said Chris Kim, CEO Liminatus.

Sumit Metha, CEO of Iris, commented,&quot;Immuno-therapies are much in-demand and we believe they are one of the most promising medical treatments for cancer. This deal presents a good opportunity for our company to tap into a rapidly growing global cancer immunotherapy market, expected to hit around&nbsp;$262 billion&nbsp;dollars by 2030. We are very confident that our investors will be excited for this deal because of the position of these treatments in their development cycle, the global demand and the excellent team of scientific advisors and executives at Liminatus.&quot;

About Liminatus Pharma LLC

Liminatus is a clinical-stage biopharmaceutical company developing novel cancer therapies that exploit the body&#39;s immune system to recognise and attack cancer cells. The development pipeline consists of chimeric antigen receptor (CAR)-T cell therapeutics, Guanylyl Cyclase C (GCC) cancer vaccine and CD47 immune checkpoint inhibitor.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Iris Acquisition

News

Latest news for Iris Acquisition (NASDAQ:IRAA) Stock

Tuesday, February 21, 2023

Thursday, December 01, 2022